Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The new approach takes advantage of the natural process by which cells break down proteins into fragments called peptides.
Promising research shows that marking the mutated KRAS protein of cancer cells can signal the immune system to destroy that cancer.
The median progression- free survival time was 6.5 months, and the median overall survival time was 12.6 months.
Experimental KRAS inhibitor adagrasib also shows activity against lung cancer that has spread to the brain.
Two-year follow-up showed that Lumakras prolonged treatment response and had a favorable safety profile.
A look back at some of the most important science and treatment news Cancer Health covered this year.
Damon Runyon Cancer Research Foundation scientists work to develop drugs for people with KRAS-driven cancers.
Targeted therapies are available for eight tumor mutations, highlighting the importance of genomic testing.
Lumakras (sotorasib) was granted accelerated approval for the treatment of advanced non-small-cell lung cancer.
Lumakras led to tumor shrinkage in 36% of NSCLC patients with KRAS G12C mutations.
The theme of this issue is the science underlying advances in cancer care and treatment.
More than 80% of lung cancer patients treated with the targeted therapy experienced remission or had stable disease.
The technology used in COVID-19 vaccines may also be used to prevent other viral infections and to treat cancer and multiple sclerosis.
Sotorasib and adagrasib target a specific cancer-causing mutation found in those with non-small-cell lung cancer and colorectal cancer.
Genomic testing can help customize treatment to target tumors.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.